 | |
| Clinical data | |
|---|---|
| Trade names | Tessie |
| Other names | ODM-105; ODM105; ORM-19695; ORM19695 |
| Routes of administration | Dogs:Oral[1][2] Humans: unspecified[3] |
| Drug class | α2A-Adrenergic receptoragonist;Anxiolytic;Sedative;Hypnotic |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H16N2O2 |
| Molar mass | 232.283 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tasipimidine (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code namesODM-105 andORM-19695), sold under the brand nameTessie, is anα2-adrenergic receptoragonist which is approved for the short-term treatment offear andanxiety in dogs.[1][4] It is also under development for the treatment ofinsomnia in humans.[2][3][5] The drug is used as anoralsolution in dogs,[1] whereas itsroute of administration for humans is unspecified.[3]
The drug acts as apotent andselectivefull agonist of the humanα2A-adrenergic receptor.[2] Conversely, it is a much weaker agonist of the rodentα2B-,α2C-, andα2D-adrenergic receptors.[2] In addition, it shows only lowaffinity forα1-adrenergic receptors, where it appears to act as apartial agonist.[2] Tasipimidine producesanxiolytic,sedative,hypolocomotor,hypotensive, andbradycardic effects in animals.[2]
Tasipimidine is under development for use in humans byOrion Corporation.[3][5] As of October 2024, it is inphase 2clinical trials for this indication.[3][5] The drug is or was also under development for the treatment ofpsychiatric disorders in humans, but no recent development for this indication has been reported.[3] It has reachedphase 1 trials for psychiatric disorders.[3] Tasipimidine was approved for treatment of fear and anxiety in dogs in theEuropean Union in 2021.[1]